Citations

Showing 10 of 108152 citations.

Intranodal Sirolimus Induces Regulatory T Cells in Human Hepatic Lymph Nodes via Interleukin 10 Signaling
Nguyen, Justin H. , Jiang, Liuyan , Lu, Kang , Malik, Sunita , Orlando, Christopher , Rehman, Fatima , Kang, Lu, Malik, Sunita, Zubair, Abba C.

Mayo Clinic

Liver Transplantation | June 16, 2021 | Volume: 27 | Issue: 11 | Pages: 1669-1672

10.1002/lt.26214 | PMID 34133835 Get It

Interlaboratory Performance in Measurement of Dabigatran and Rivaroxaban
Goodwin, Andrew , Higgins, Russell A. , Long, Thomas , Chandler, Wayne L. , Harris, Neil , Isom, James , Moser, Karen , Olson, John D. , Smock, Kristi J. , VanSandt, Amanda M., Chen, Dong , Chen, Dong , Volod, Oksana , Rollins‐Raval, Marian A. , Pham, Huy P. , Wool, Geoffrey D.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | June 16, 2021 | Volume: 146 | Issue: 2 | Pages: 145-153

10.5858/arpa.2020-0633-cp | PMID 34133726 Get It

Context.— Assessing direct oral anticoagulant (DOAC) drug levels by reliable laboratory assays is necessary in a number of clinical scenarios. Objective.— To evaluate the performance of DOAC-specific assays for various concentrations of dabigatran and rivaroxaban, assess the interlaboratory variability in measurement of these DOACs, and investigate the responsiveness of the routine clotting assays to various concentrations of these oral anticoagulants. Design.— College of American Pathologists proficiency testing survey data from 2013 to 2016 were summarized and analyzed. Results.— For dabigatran, the interlaboratory coefficient of variation (CV) of ecarin chromogenic assay was broad (ranging from 7.5% to 29.1%, 6.3% to 15.5%, and 6.8% to 9.0% for 100-ng/mL, 200-ng/mL, and 400-ng/mL targeted drug concentrations, respectively). The CV for diluted thrombin time for dabigatran was better overall (ranging from 11.6% to 17.2%, 9.3% to 12.3, and 7.1% to 11.2% for 100 ng/mL, 200 ng/mL, and 400 ng/mL, respectively). The rivaroxaban-calibrated anti-Xa assay CVs also showed variability (ranging from 11.5% to 22.2%, 7.2% to 10.9%, and 6.4% to 8.1% for 50-ng/mL, 200-ng/mL, and 400-ng/mL targeted drug concentrations, respectively). The prothrombin time (PT) and activated partial thromboplastin time (aPTT) showed variable dose- and reagent-dependent responsiveness to DOACs: PT was more responsive to rivaroxaban and aPTT to dabigatran. The undiluted thrombin time showed maximum prolongation across all 3 dabigatran concentrations, making it too sensitive for drug-level monitoring, but supporting its use as a qualitative screening assay. Conclusions.— DOAC-specific assays performed reasonably well. While PT and aPTT cannot be used safely to determine DOAC degree of anticoagulation, a normal thrombin time excludes the presence of dabigatran.
Impact of delayed device re‐implantation on outcomes of patients with cardiovascular implantable electronic device related infective endocarditis
Arshad, Verda , Lahr, Brian D. , Khalil, Sarwat , Tariq, Wajeeha , Talha, Khawaja M. , Cha, Yong‐Mei , DeSimone, Daniel C. , Talha, Khawaja Muhammad, Cha, Yong-Mei , DeSimone, Daniel C , Baddour, Larry M. , Sohail, M. Rizwan

Mayo Clinic

Pacing and Clinical Electrophysiology | June 16, 2021 | Volume: 44 | Issue: 8 | Pages: 1303-1311

10.1111/pace.14297 | PMID 34132396 Get It

AbstractBackgroundOptimal timing of cardiovascular implantable electronic device (CIED) re‐implantation following device removal due to infection is undefined. Multinational guidelines reflect this and include no specific recommendation for this timing, while others have recommended waiting at least 14 days in cases of CIED related infective endocarditis (CIED‐IE). The current work seeks to clarify this issue.MethodsWe retrospectively reviewed institutional data at Mayo Clinic, Minnesota of patients aged ≥ 18 years who developed CIED‐IE from January 1, 1991 to February 1, 2016. CIED‐IE was defined as echocardiogram reported device lead or valvular vegetation. Regression analyses were used to relate the risk of clinical outcomes to the interval between CIED removal and re‐implantation and the location of vegetations.ResultsA total of 109 patients met study inclusion criteria. A majority (68.8%) of patients were men and the median age was 68.0 years. Transoesophageal echocardiogram (TEE) was performed in 95.4% of patients, with valve vegetations detected in 33.9% (n = 37). Survival analysis comparing patients in whom device re‐implantation was < 14 days vs. ≥14 days, and further categorized by those with and without valve vegetation, showed a significant difference (P = 0.028); patients with valve vegetation and reimplantation interval < 14 days had the lowest (58.7%) 12‐month survival. When adjusted for valve vegetation, longer time interval for reimplantation trended toward increased hospital length of stay (P = 0.079).ConclusionOur findings suggest that the recommended 14‐day delay between CIED extraction and re‐implantation in CIED‐IE patients is associated with a survival benefit, but longer length of hospital stay following re‐implantation.
Midterm Outcomes of a Prospective, Nonrandomized Study to Evaluate Endovascular Repair of Complex Aortic Aneurysms Using Fenestrated-Branched Endografts
Oderich, Gustavo S. , Tenorio, Emanuel R. , Mendes, Bernardo C. , Lima, Guilherme Baumgardt Barbosa , Saqib, Naveed, Hofer, Jan , Wong, Joshua , Macedo, Thanila A. , Tenorio, Emanuel R , Lima, Guilherme B , Oderich, Gustavo S. , Marcondes, Giulianna B. , Wong, Joshua

Mayo Clinic

Annals of Surgery | June 16, 2021 | Volume: 274 | Issue: 3 | Pages: 491-499

10.1097/sla.0000000000004982 | PMID 34132698 Get It

Objective: The aim of this study was to investigate the midterm outcomes of fenestrated and branched endovascular aortic repair (FB-EVAR) of pararenal (PRA) and thoracoabdominal aortic aneurysms (TAAAs). Summary Background Data: FB-EVAR has been associated with decreased morbidity compared to open repair, but there is limited midterm data. Methods: A total of 430 patients (302 males, mean age 74 ± 8 years) treated by FB-EVAR were enrolled in a prospective, nonrandomized investigational device exemption study. Endpoints included 30-day mortality and major adverse events (MAEs), freedom from all cause and aortic-related mortality, target vessel patency, and freedom from secondary intervention and target vessel instability. Results: There were 133 PRAs and 297 TAAAs with 1673 renal-mesenteric arteries incorporated by fenestrations or directional branches (3.9 ± 0.5 vessels/patient). At 30 days or within the hospital stay if longer than 30 days, there were 4 (0.9%) deaths. MAEs included new-onset dialysis in 8 patients (2%), permanent paraplegia or stroke in 10 patients each (2%), and respiratory failure requiring tracheostomy in 2 patients (0.5%). After a mean follow-up of 26 ± 20 months, there were 3 (0.7%) aortic-related deaths from SMA stent occlusion, gastrointestinal hemorrhage, or complications of open arch repair. At 5 years, freedom from all-cause and aortic-related mortality were 57% ± 5% and 98% ± 1%, respectively. Freedom from secondary intervention was 64% ± 4%, primary target vessel patency was 94% ± 1%, and freedom from target vessel instability was 89% ± 2% at same interval. One patient (0.2%) had nonfatal aneurysm treated using endovascular repair. Conclusion: FB-EVAR is safe and effective for treatment of PRA and TAAAs with low rate of aortic-related mortality and aneurysm rupture on midterm follow-up.
Guidelines for genetic testing of muscle and neuromuscular junction disorders
Nicolau, Stefan , Milone, Margherita , Liewluck, Teerin , Liewluck, T , Nicolau, Stefan

Mayo Clinic

Muscle & Nerve | June 16, 2021 | Volume: 64 | Issue: 3 | Pages: 255-269

10.1002/mus.27337 | PMID 34133031 Get It

Abstract Despite recent advances in the understanding of inherited muscle and neuromuscular junction diseases, as well as the advent of a wide range of genetic tests, patients continue to face delays in diagnosis of sometimes treatable disorders. These guidelines outline an approach to genetic testing in such disorders. Initially, a patient's phenotype is evaluated to identify myopathies requiring directed testing, including myotonic dystrophies, facioscapulohumeral muscular dystrophy, oculopharyngeal muscular dystrophy, mitochondrial myopathies, dystrophinopathies, and oculopharyngodistal myopathy. Initial investigation in the remaining patients is generally a comprehensive gene panel by next‐generation sequencing. Broad panels have a higher diagnostic yield and can be cost‐effective. Due to extensive phenotypic overlap and treatment implications, genes responsible for congenital myasthenic syndromes should be included when evaluating myopathy patients. For patients whose initial genetic testing is negative or inconclusive, phenotypic re‐evaluation is warranted, along with consideration of genes and variants not included initially, as well as their acquired mimickers.
Successful encorafenib desensitization in a patient with recurrent metastatic melanoma
Cullen, Grace , Finnes, Heidi D. , Volcheck, Gerald W., Cullen, Grace D , Markovic, Svetomir N.

Mayo Clinic

Melanoma Research | June 16, 2021 | Volume: 31 | Issue: 4 | Pages: 402-404

10.1097/cmr.0000000000000757 | PMID 34193805 Get It

Type I hypersensitivity reactions (HSR) to dabrafenib are rare but have been previously described. We present a case where a 72-year-old woman with recurrent, metastatic BRAF-mutated melanoma developed a type I HSR to dabrafenib. We, therefore, developed a desensitization protocol with encorafenib, a similar class agent, to allow the patient to continue with treatment. Patients with a history of HSR to dabrafenib may be considered for encorafenib desensitization when other therapeutic options are limited.
Ten‐year clinical outcomes in patients with intermediate coronary stenosis according to the combined culprit lesion
Kim, Yong Kyun , Jang, Chae Won , Kwon, Soon Ho , Kim, Jae Hoon , Lerman, Amir , Bae, Jang‐Ho , Lerman, Amir

Mayo Clinic

Clinical Cardiology | June 16, 2021 | Volume: 44 | Issue: 8 | Pages: 1161-1168

10.1002/clc.23668 | PMID 34133033 Get It

AbstractBackgroundWe assessed the long‐term clinical outcomes of an intermediate lesion (IL) according to the presence of a combined culprit lesion (CCL).HypothesisLong‐term clinical outcomes of IL may be affected by the presence of a CCL.MethodsAngiographic findings (n = 1096) and medical chart were reviewed. Patients with IL were divided into two groups: IL without CCL group (n = 383, 64.5%) and IL with CCL group (n = 211, 35.5%).ResultsThe major adverse cardiovascular events (MACE) in the IL with CCL group were significantly higher than those in the IL without CCL group (death: 12.3% vs. 7.0%, myocardial infarction: 3.3%vs. 0.5%, stroke: 6.6% vs. 2.6%, and revascularization [RVSC]: 25.1% vs. 7.6%) during a mean follow up period of 118.4 ± 5.5 months. IL related RVSC rate in the IL with CCL group was higher than that in the IL without CCL group (5.7% vs. 2.1%, p = 0.020). RVSC rate related to IL in total subjects was lower than that related to stented lesion (3.4% vs. 6.4%). The important predictors of total MACE in total subjects were the presence of CCL, IL percent diameter stenosis, hypertension, history of percutaneous coronary intervention, blood glucose and ejection fraction. The predictors of IL related RVSC were IL percent diameter stenosis and IL located in the right coronary artery.Conclusion10‐year clinical outcomes of an IL (especially IL without CCL) were better than those of stented lesions. This study suggests that the IL can be safely followed up in sites that do not have ability to assess functional study.
Clinical Effect of Systemic Steroids in Patients with Cirrhosis and Septic Shock
Serafim, Laura Piccolo, Simonetto, Douglas A., Anderson, Alexandra L., Choi, Dae Hee, Weister, Timothy J., Hanson, Andrew C., Kamath, Patrick S., Gajic, Ognjen, Moraes, Alice Gallo de, Simonetto, Douglas A. , Piccolo Serafim, Laura, Simonetto, Douglas A , Serafim, Laura Piccolo, Anderson, Alexandra L., Choi, Dae Hee, Weister, Timothy J., Hanson, Andrew C., Kamath, Patrick S., Gajic, Ognjen, Moraes, Alice Gallo de

Mayo Clinic

Shock | June 16, 2021 | Volume: 56 | Issue: 6 | Pages: 916-920

10.1097/shk.0000000000001822 | PMID 34132218 Get It

ABSTRACT Purpose: Evidence regarding the utility of systemic steroids in treating patients with cirrhosis and septic shock remains equivocal. This study aimed to evaluate and elucidate the association of steroid use with outcomes and adverse effects in a cohort of patients with cirrhosis and septic shock. Patients and methods: Retrospective cohort study of patients with cirrhosis and septic shock admitted to a tertiary hospital intensive care unit (ICU) from January 2007 to May 2017, using a validated ICU Datamart. Patients who received vasopressors within 6 h of ICU admission were included in the multivariate analysis. The effect of steroids on outcomes was evaluated using multivariable regression, adjusting for confounding variables. Results: Out of 179 admissions of patients with cirrhosis and septic shock, 56 received steroids during the ICU admission. Patients who received steroids received a higher total dose of vasopressors (91.2 mg vs. 39.1 mg, P = 0.04) and had a lower initial lactate level (1.8 mmol/L vs. 2.6 mmol/L, P = 0.007). The multivariate analysis included 117 patients and showed no significant differences in mortality, length of ICU admission, or length of hospital stay. Bleeding events, delirium, and renal-replacement therapy requirements were also not associated with the use of steroids. Conclusion: The use of systemic steroids was more prevalent in cirrhotic patients with higher vasopressor requirements. It was not associated with decreased mortality or increased ICU- and hospital-free days, or to adverse effects.
Intravenous infusion of Bendavia during renal revascularization attenuates cardiac injury and dysfunction in swine renovascular hypertension (RVH)
Williams, Barbara, Zhang, Xin , Woollard, John R. , Jordan, Kyra L., Crane, John A., Lerman, Lilach O. , Eirin, Alfonso , Ebrahimi, Behzad , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

The FASEB Journal | June 16, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.1131.14 Get It

Percutaneous transluminal renal angioplasty and stenting (PTRS) for RVH may not revert the secondary cardiac dysfunction and remodeling. In experimental RVH, infusion of the tetrapeptide Bendavia (that inhibits mitochondrial permeability transition pore opening) during PTRS attenuated stenotic kidney inflammatory injury and improved its function. We hypothesized that adjunct Bendavia during PTRS would also attenuate cardiac remodeling after reversal of RVH. RVH was induced in 18 pigs, of which 6 were sham treated (RVH) and 12 underwent PTRS plus a 4h IV infusion of Bendavia (0.05 mg/kg) or vehicle (n=6, each); 6 normal pigs served as controls. Cardiac oxygenation and function were assessed 4 wks later by blood oxygen level‐dependent (BOLD)‐MRI and CT, and tissue studies performed. PTRS normalized blood pressure (Table). Systolic function was unchanged. Apoptotic activity (caspase‐3), hypoxia (BOLD‐R2*), inflammation (TNF‐α, IL‐6), and fibrosis (trichrome) remained elevated and diastolic function (E/A) impaired in PTRS+Vehicle, but all improved in PTRS+Bendavia (Figure). Thus, novel cardioprotective properties of Bendavia enhance cardiac recovery after reversal of experimental RVH, and may provide a novel therapeutic option.
Assessing the quality of dissection: A method for improving anatomy knowledge of first year medical students
Lachman, Nirusha , Pawlina, Wojciech, Nwachukwu, Chika

Mayo Clinic

The FASEB Journal | June 16, 2021 | Volume: 27 | Issue: S1 | Pages: No page available

10.1096/fasebj.27.1_supplement.318.6 Get It

Anatomy learned by active exploration in the dissection laboratory has been shown to be beneficial in improving anatomic knowledge, promoting self‐reflection, teamwork, and professionalism. Decreased dissection time may affect the quality of dissection and ultimately retention of gross anatomy knowledge. This could translate to lower student performance in the anatomy course. The purpose of this study was to determine whether evaluating the quality of students’ dissection has an effect on practical examinations performance, mid and end‐course evaluations. Quality of dissections for each team enrolled in a gross anatomy course at Mayo Medical School was evaluated bi‐weekly. Each member of the dissection team received the same score which was calculated towards 5% of their final grade. Dissections were evaluated using a five‐point rubric that incorporates measures for determining whether students had met laboratory learning objectives. Assessment of anatomic knowledge was based on laboratory practical exam scores recorded at intervals throughout the course and achievements on daily audience response system quizzes. Increase in quality of dissection was associated with improvement in practical exams. Teams that received lower dissection scores had lower scores on practical exams. Our results imply that students who achieve daily dissection goals, perform better on the practical examinations. Grant Funding Source : Department of Anatomy